Study of 0.4% povidone-iodine nasal spray for SARS-CoV-2
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
Source: dovepress.com
Stay updated with breaking news from Reporting Parallel Group Randomised. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
Continuous Erector Spinae Plane Block Using Programmed Intermittent Bolus Regimen versus Intravenous Patient-Controlled Opioid Analgesia Within an Enhanced Recovery Program After Open Liver Resection in Patients with Coagulation Disorder: A Randomized, Controlled, Non-Inferiority Trial